Sanofi – NASDAQ:SNY
Sanofi stock price today
$50
+1.27
+2.61%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Sanofi stock price monthly change
-5.07%
month
Sanofi stock price quarterly change
-5.07%
quarter
Sanofi stock price yearly change
-2.05%
year
Sanofi key metrics
Market Cap | 118.93B |
Enterprise value | 133.61B |
P/E | 12.99 |
EV/Sales | 2.24 |
EV/EBITDA | 11.86 |
Price/Sales | 1.95 |
Price/Book | 0.80 |
PEG ratio | -3.92 |
EPS | 5.77 |
Revenue | 57.38B |
EBITDA | 17.62B |
Income | 7.06B |
Revenue Q/Q | 2.34% |
Revenue Y/Y | 24.20% |
Profit margin | 7.57% |
Oper. margin | 21.72% |
Gross margin | 67.89% |
EBIT margin | 21.72% |
EBITDA margin | 30.71% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSanofi stock price history
Sanofi stock forecast
Sanofi financial statements
| Jun 2023 | 10.68B | 1.43B | 13.43% |
|---|---|---|---|
| Sep 2023 | 12.69B | 2.52B | 19.89% |
| Dec 2023 | 22.88B | 1.97B | 8.61% |
| Mar 2024 | 11.11B | 1.13B | 10.19% |
| 2025 | 54.30B | 5.38B | 9.92% |
|---|---|---|---|
| 2026 | 57.66B | 5.89B | 10.22% |
| 2027 | 60.84B | 6.33B | 10.41% |
| 2028 | 63.38B | 6.94B | 10.96% |
Analysts Price target
Financials & Ratios estimates
| 2022-10-28 | 1.33 | 1.44 |
|---|---|---|
| 2022-12-31 | 0.663 | 0.582 |
| 2023-02-03 | 0.896 | 0.87 |
Paying a dividend greater than earnings.
3.16%
Yield TTM
| Payout ratio | 104.39% |
|---|
| 2019 | 6.85% |
|---|---|
| 2020 | 7.9% |
| 2021 | 7.26% |
| 2022 | 7.36% |
| 2023 | 7.87% |
| Jun 2023 | 125353000000 | 52.40B | 41.81% |
|---|---|---|---|
| Sep 2023 | 0 | 0 | |
| Dec 2023 | 126464000000 | 52.11B | 41.21% |
| Mar 2024 | 0 | 0 |
| Jun 2023 | 3.56B | -3.07B | -5.21B |
|---|---|---|---|
| Sep 2023 | 0 | 0 | 0 |
| Dec 2023 | 6.69B | -3.12B | -2.83B |
| Mar 2024 | 0 | 0 | 0 |
Sanofi alternative data
| Sep 2023 | 91,573 |
|---|---|
| Oct 2023 | 91,573 |
| Nov 2023 | 91,573 |
| Dec 2023 | 91,573 |
| Jan 2024 | 91,573 |
| Feb 2024 | 91,573 |
| Mar 2024 | 86,088 |
| Apr 2024 | 86,088 |
| May 2024 | 86,088 |
| Jun 2024 | 86,088 |
| Jul 2024 | 86,088 |
Sanofi other data
19.96%
+0.52%
of SNY is owned by hedge funds
590
-6
251.03M
+7.04M
shares is hold by hedge funds
| Patent |
|---|
Grant Utility: Live-attenuated yellow fever virus strain adapted to grow on Vero cells and vaccine composition comprising the same Filling date: 5 Nov 2021 Issue date: 27 Sep 2022 |
Grant Filling date: 28 Jul 2020 Issue date: 27 Sep 2022 |
Grant Utility: Medicament delivery device Filling date: 20 Sep 2017 Issue date: 27 Sep 2022 |
Grant Utility: Drug delivery device Filling date: 26 Apr 2019 Issue date: 20 Sep 2022 |
Grant Filling date: 14 Jan 2020 Issue date: 13 Sep 2022 |
Grant Filling date: 12 Nov 2018 Issue date: 13 Sep 2022 |
Grant Utility: Medicament delivery device Filling date: 21 Dec 2017 Issue date: 13 Sep 2022 |
Grant Utility: Injection device Filling date: 21 Nov 2016 Issue date: 13 Sep 2022 |
Application Filling date: 5 May 2022 Issue date: 1 Sep 2022 |
Application Filling date: 16 Feb 2022 Issue date: 1 Sep 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 25 Apr 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 1 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q1 2023 9 Jan 2024 | Q1 2023 Earnings Call Transcript |
| Q3 2023 27 Oct 2023 | Q3 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Paul Hudson (1967) Chief Executive Officer & Director | $6,410,000 |
Why Johnson & Johnson Stock Still Has Room To Run
GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval
Sanofi: A Solid EU Contrarian Play
Why Novartis Is Still A 'Buy' After 15% Surge
Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025
Medicus Pharma: High-Risk, But Higher Reward For Their Potential Breakthrough Skin Cancer Treatment
Merck: Don't Let Today's Bargain Opportunity Pass You By
Nektar Therapeutics Scores Big Phase 2b Win With REZPEG
Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade
-
What's the price of Sanofi stock today?
One share of Sanofi stock can currently be purchased for approximately $50.
-
When is Sanofi's next earnings date?
Unfortunately, Sanofi's (SNY) next earnings date is currently unknown.
-
Does Sanofi pay dividends?
Yes, Sanofi pays dividends and its trailing 12-month yield is 3.16% with 104% payout ratio.It means that the company is paying a dividend greater than earnings. The last Sanofi stock dividend of $1.93 was paid on 26 May 2021.
-
How much money does Sanofi make?
Sanofi has a market capitalization of 118.93B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 1.42% to 46.03B US dollars. Sanofi earned 5.4B US dollars in net income (profit) last year or $0.87 on an earnings per share basis.
-
What is Sanofi's stock symbol?
Sanofi is traded on the NASDAQ under the ticker symbol "SNY".
-
What is Sanofi's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - General industry.
-
How do i buy shares of Sanofi?
Shares of Sanofi can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Sanofi's key executives?
Sanofi's management team includes the following people:
- Mr. Paul Hudson Chief Executive Officer & Director(age: 58, pay: $6,410,000)
-
How many employees does Sanofi have?
As Jul 2024, Sanofi employs 86,088 workers.
-
When Sanofi went public?
Sanofi is publicly traded company for more then 23 years since IPO on 1 Jul 2002.
-
What is Sanofi's official website?
The official website for Sanofi is sanofi.com.
-
How can i contact Sanofi?
Sanofi can be reached via phone at +33 1 53 77 40 00.
Sanofi company profile:
Sanofi
sanofi.comExchange:
NASDAQ
Full time employees:
86,088
Industry:
Drug Manufacturers - General
Sector:
Healthcare
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
54, Rue La BoEtie
Paris, 75008
Paris, 75008
CIK: 0001121404
ISIN: US80105N1054
CUSIP: 80105N105
